

DFV



CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
5-22-06	<i>Barbara R. Smith</i>
Date	Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	
Ozaki et al.	§	Group Art Unit: 1644
	§	
Serial No.: 10/726,195	§	Examiner: Not yet assigned
	§	
Confirmation No.: 5902	§	Atty. Docket: 13240.0004.CNUS02
	§	
Filed: December 2, 2003	§	
	§	
For: DIAGNOSTIC DRUGS FOR AUTO	§	
IMMUNE DISEASES	§	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the current application. Copies of references C14-C20 are supplied herewith.

In accordance with 37 C.F.R. § 1.97(g) and (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, or as

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

It is believed that this paper is being filed before an Office Action on the merits of the application has been sent; therefore no fee is believed to be due. However, should any fees be required for any reason in connection with this paper, the Commissioner is authorized to deduct said fees from Howrey Deposit Account No. 08-3038/13240.0004.CNUS02.

Respectfully submitted,



J. Wendy Davis, Ph.D.
Reg. No. 46,393
Agent for Assignee
KANEKA CORPORATION

Customer No. 23369
HOWREY LLP
1111 Louisiana, 25th Floor
Houston, Texas 77002
(713) 787-1512 (direct)

Date: May 22, 2006

Form PTO-1449 (modified)Atty. Docket No.
13240.0004.CNUS02Serial No.
10/726,195

List of Patents and Publications for Applicant's

Applicants:
Shoichi Ozaki**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Filing Date:
December 2, 2003Group:
1644**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Wen, L. <i>et al.</i> , "A Human Placental cDNA Clone That Encodes Nonhistone Chromosomal Protein HMG-1", Nucleic Acids Research, Volume 17, Number 3, 1989, pp 1197-1214.
	C15	Kaplan, D. <i>et al.</i> , "Full Length cDNA Sequence For Bovine High Mobility Group 1 (HMG1) Protein", Nucleic Acids Research, Volume 16, Number 21, 1988, pp 10375.
	C16	Tsuda K. <i>et al.</i> , "Primary Structure of Non-Histone Protein HMG1 Revealed by the Nucleotide Sequence", Biochemistry, Volume 27, 1988, pp 6159-6163.
	C17	Paonessa, G. <i>et al.</i> , "Nucleotide Sequence of Rat Liver HMG1 cDNA", Nucleic Acids Research, Volume 15, Number 21, 1987, pp 9077.
	C18	Shirakawa, H. <i>et al.</i> , "Structure of a Gene Coding for Human HMG2 Protein", The Journal of Biological Chemistry, Volume 267, Number 10, 1992, pp 6641-6645.
	C19	Shirakawa, H. <i>et al.</i> , "Primary Structure of Non-Histone Chromosomal Protein HMG2 Revealed by the Nucleotide Sequence", Biochemistry, Volume 29, 1990, pp 4419-4423.
	C20	Bucci, L. <i>et al.</i> , "Characterization of High Mobility Group Protein Levels during Spermatogenesis in the Rat," The Journal of Biological Chemistry, Volume 259, Number 14, 1984, pp 8840-8846.

Examiner:

Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Information Disclosure Statement — PTO-1449 (Modified)